Author
President Trump’s recent executive order directing federal agencies to finalize the rescheduling of cannabis from Schedule I to Schedule III marks a watershed moment in American drug policy.
By Vincent Joralemon Pharmaceutical advertisers want health data so that they can effectively tailor the $18 billion spent annually on drug pitches to those audiences most likely to buy these products. However, a recent privacy…
By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. For example, experts…
FDA rescheduling may provide a compelling model for efforts to decriminalize and destigmatize other substances moving forward.
Lykos’ current application is based on MDMA-assisted therapy, and FDA will almost surely require that patients take the drug in a clinical setting.
The telemedicine extension is not just for psychedelics; easing these restrictions means relaxing them for other controlled substances as well.
Not all lobbying campaigns are problematic — the goal should be for regulators to leverage industry insights while maintaining independence in decision-making.
There is little consensus in defining “psychedelic.” Yet, research on and access to these substances hinges on what gets included under this umbrella.
A combination of high demand and a patent monopoly has created a perfect storm of profitability for Janssen’s Spravato.
The most effective way to change peoples’ opinions is to highlight the success stories of those who have tried psychedelics.
